MarketPulse
D

$DNOW

5 articles found
0 positive
5 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Stock Plummets 71% After FDA Rejects Lead Drug; Law Firm Launches Investigation

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.
ITDNOWALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

DNOW Stock Plunges 19% After Missing Q4 Targets; Class Action Probe Launched

DNOW Inc. stock fell 19.1% following disappointing Q4 2025 results that missed expectations, triggering securities investigation and class action lawsuit.
DNOWsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

DNOW Stock Plummets 19% on Weak Q4 Results; Class Action Investigation Launched

DNOW shares fell 19.1% after missing Q4 2025 earnings expectations. The Rosen Law Firm is investigating potential securities claims on behalf of affected investors.
DNOWsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Rosen Law Firm

DNOW Stock Plunges 19% on Missed Earnings; Law Firm Probes Securities Claims

DNOW Inc. shares crashed 19.1% after disappointing Q4 2025 results. The Rosen Law Firm is investigating potential securities violations for investor compensation.
DNOWstock declineinvestor losses
The Motley FoolThe Motley Fool··Eric Volkman

Distributech International Shares Fall 19% on Earnings Miss Despite Revenue Growth

Distributech shares fell 19% after missing earnings expectations despite doubling revenue from MRC Global acquisition. Integration challenges with legacy systems raised investor concerns about synergy timelines.
DNOWearnings missrevenue growth